CClinicalTrials.gg
Status unknownNCT00772993Updated Oct 16, 2008

Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma

An observational study in Glaucoma and Myopia, sponsored by Yonsei University. Status unknown at 1 site in Korea, Republic of. Open to participants aged 10 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-10-16.

Sponsored by Yonsei University · Observational

The sponsor has not verified this record recently (last verified Oct 2008), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Time perspective
Prospective
Enrollment
400
Ages
10 Years to 90 Years
Sex
All
01

Study summary

Glaucoma is presumed to be an axonal disease which starts at the lamina cribrosa. This assumption has led to the monitoring of the retinal nerve fiber layer thickness for the diagnosis and monitoring of progression of glaucoma. However, varying disc size, myopia and tilted discs affect the thickness of the retinal nerve fiber layer. This study aims to ascertain the ration of the retinal nerve fiber layer against full retina as a predictor of glaucoma diagnosis and progression.

02

Conditions studied

  • Glaucoma
  • Myopia

Browse trials for

Keywords

  • glaucoma
  • myopia
  • myopia with glaucoma
  • normal control
03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 400 is above the median of 103 across 454 observational studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Yonsei University is the lead sponsor of 1,387 studies on the registry; 232 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

prospective consecutive recruitment from a tertialry glaucoma subspecialty practise

Inclusion criteria

  • Primary open angle glaucoma
  • Myopia
  • Myopia with evidence of glaucoma
  • Normal controls

Exclusion criteria

Exclusion Criteria:

  • Evidence of retinal disease
  • BCVA \< 0.4
  • Secondary glaucoma due to intraocular inflammation
  • Lens induced glaucoma
  • Tumor induced glaucoma
  • Neovascular glaucoma
05

Study design

Time perspective
Prospective
Enrollment
400 participants (estimated)

Groups and cohorts

  • 1

    Primary open angle glaucoma

  • 2

    Normal Control

  • 3

    Myopia with no evidence of glaucoma

  • 4

    Myopia with evidence og glaucoma

06

What researchers measure

Primary outcomes

  1. Ratio of RNFL / Full thickness retina

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
  • Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine
    Seoul, 120-752, Korea, Republic of
    • Chan Yun Kim, MD,PhD · Contact · kangeye@hotmail.com · 82-2-2228-3570
    • Chan Yun Kim, MD,PhD. · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 16, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00772993
Lead sponsor
Yonsei University
First posted
Oct 16, 2008
Start date
Oct 2008
Primary completion
Dec 2008 (estimated)
Completion
Dec 2008 (estimated)
Last update
Oct 16, 2008

Study contacts

Chan Yun Kim, MD,PhD.
Contact
kangeye@hotmail.com
82-2-2228-3570
Sung Yong Kang, MD
Contact
kangeye@yuhs.ac
82-2-2228-3570

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion